Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,071,873
  • Shares Outstanding, K 72,768
  • Annual Sales, $ 77,800 K
  • Annual Income, $ -281,310 K
  • 60-Month Beta 1.05
  • Price/Sales 12.98
  • Price/Cash Flow N/A
  • Price/Book 39.54
Trade RVNC with:

Options Overview Details

View History
  • Implied Volatility 70.32% ( -3.03%)
  • Historical Volatility 66.17%
  • IV Percentile 19%
  • IV Rank 14.14%
  • IV High 160.62% on 05/11/22
  • IV Low 55.44% on 05/26/21
  • Put/Call Vol Ratio 0.18
  • Today's Volume 630
  • Volume Avg (30-Day) 517
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 17,233
  • Open Int (30-Day) 17,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.89
  • Number of Estimates 5
  • High Estimate -0.66
  • Low Estimate -1.16
  • Prior Year -1.07
  • Growth Rate Est. (year over year) +16.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.66 +22.43%
on 05/12/22
18.61 -16.71%
on 04/18/22
-3.10 (-16.67%)
since 04/14/22
3-Month
11.65 +33.05%
on 02/24/22
20.74 -25.27%
on 04/05/22
+2.32 (+17.60%)
since 02/17/22
52-Week
11.65 +33.05%
on 02/24/22
33.83 -54.18%
on 07/09/21
-13.65 (-46.83%)
since 05/17/21

Most Recent Stories

More News
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RVNC : 15.59 (+5.84%)
YMTX : 1.1171 (+3.44%)
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2022...

RVNC : 15.59 (+5.84%)
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TWST : 33.83 (+4.74%)
RVNC : 15.59 (+5.84%)
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter...

RVNC : 15.59 (+5.84%)
Noteworthy Friday Option Activity: RVNC, GPS, PGEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Revance Therapeutics Inc , where a total of 6,325 contracts have traded so far, representing...

RVNC : 15.59 (+5.84%)
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted...

RVNC : 15.59 (+5.84%)
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced they will give one oral presentation and present one poster...

RVNC : 15.59 (+5.84%)
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?

Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price...

RVNC : 15.59 (+5.84%)
BGNE : 138.62 (+7.31%)
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the closing of a $300 million note purchase...

RVNC : 15.59 (+5.84%)
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter...

RVNC : 15.59 (+5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined...

See More

Key Turning Points

3rd Resistance Point 16.49
2nd Resistance Point 15.70
1st Resistance Point 15.21
Last Price 15.59
1st Support Level 13.93
2nd Support Level 13.14
3rd Support Level 12.65

See More

52-Week High 33.83
Fibonacci 61.8% 25.36
Fibonacci 50% 22.74
Fibonacci 38.2% 20.12
Last Price 15.59
52-Week Low 11.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar